Key facts
- It has raised $6.2M; the latest was Angel (individual) ($6.2M) in Jan 2025.
- Notable investors include Creative Destruction Lab, University of Toronto, University of Toronto Entrepreneurship, Anjac, Paris Biotech Sante — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for CERES BRAIN Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for CERES BRAIN Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CERES BRAIN Therapeutics
Developer of a medical platform designed to administrate medicine to the brain via the olfactory and trigeminal nerves. The company's platform aims to unlock the brain's access to therapeutics, enabling doctors to cure cerebral diseases.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2019
- Employees
- 9
- Website
- ceres-brain.com/
- Ownership
- Privately Held (backing)
CERES BRAIN Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CERES BRAIN Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CERES BRAIN Therapeutics in its N-PORT filings yet. We sweep new filings monthly.